AbbVie Acquires Neuroscience Drugmaker Cerevel Therapeutics for $8.7 Billion

AbbVie has acquired Cerevel Therapeutics for $8.7 billion.
Cerevel brings with it drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis.
The deal values Cerevel Therapeutics at $45 per share.
This is AbbVie's second billion-dollar acquisition in less than a week, following its purchase of Immunogen for $10 billion.

Pharmaceutical giant AbbVie has announced its acquisition of neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. This move is part of AbbVie's strategy to expand its drug pipeline and address the generic competition faced by its top-selling treatments. Cerevel brings with it drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis. AbbVie expects the acquisition to be completed in the middle of 2024.

This marks AbbVie's second billion-dollar acquisition in less than a week, following its purchase of Immunogen and its ovarian cancer treatment for $10 billion. The deal values Cerevel Therapeutics at $45 per share. With this deal, AbbVie will gain access to several clinical-stage molecules for neurological and psychiatric disorders, further strengthening its portfolio in these areas.

Confidence

100%

No Doubts Found At Time Of Publication

Sources

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

CNBC News Annika Kim Wednesday, 06 December 2023 22:06
  • Unique Points
    • This move is part of AbbVie's strategy to expand its drug pipeline and address the generic competition faced by its top-selling treatments.
    • Cerevel brings with it drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis.
    • AbbVie expects the acquisition to be completed in the middle of 2024.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

The Wall Street Journal Ben Glickman Wednesday, 06 December 2023 21:46
  • Unique Points
    • This is AbbVie's second major acquisition in the last two weeks, following the acquisition of ImmunoGen for $10 billion.
    • The deal values Cerevel Therapeutics at $45 per share.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    • The article is straightforward and factual, with no apparent deception.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT News Jason Mast Wednesday, 06 December 2023 22:05
  • Unique Points
    • This marks AbbVie's second billion-dollar acquisition in less than a week, following its purchase of Immunogen and its ovarian cancer treatment for $10 billion.
    • The author of the article is Jason Mast, a general assignment reporter at STAT.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication